CLSA Study: FDA Review Times For New Drugs Steadily Improving

March 31, 2016 at 7:05 PM
A California Life Sciences Association report released Tuesday (March 29) shows that FDA average review times for new drugs have steadily decreased from 21 months in 2009 to 10 months in 2015. The report says the Breakthrough Therapy designation has played a major role in accelerating review times overall. But it also shows that some therapeutic areas still lag behind, leading CLSA to conclude that more can be down to speed up the process. "As demonstrated by the continued reduction...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.